WINDTREE THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1992-11-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.windtreetx.com
Clinical Trials
18
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
A Multicenter, Randomized, Placebo-Controlled, Parallel Group Trial on the Safety and Efficacy of Istaroxime for Cardiogenic Shock SCAI Stage C (SEISMiC-C)
- Conditions
- Cardiogenic Shock
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Windtree Therapeutics Inc.
- Target Recruit Count
- 80
- Registration Number
- 2023-507243-11-02
- Locations
- 🇨🇿
Fakultni Nemocnice U Sv Anny V Brne, Brno-Stred, Czechia
🇨🇿Nemocnice AGEL Trinec-Podlesi a.s., Konska, Czechia
🇨🇿Institute For Clinical And Experimental Medicine, Prague, Czechia
The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)
- Conditions
- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)COVID-19
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04389671
- Locations
- 🇺🇸
University California San Diego - Jacobs Medical Center, La Jolla, California, United States
🇺🇸University of California San Diego - Medical Center, Hillcrest, San Diego, California, United States
🇺🇸Augusta University Health, Augusta, Georgia, United States
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT04325035
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇦🇷Hospital Italiano de Bueno Aires, Capital Federal, Buenos Aires, Argentina
🇦🇷Santorio Guemes, Capital Federal, Buenos Aires, Argentina
A Safety and Efficacy Study of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age
- Conditions
- Respiratory Distress Syndrome, Newborn
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT04264156
- Locations
- 🇵🇱
Szpital Specjalistyczny nr 2 w Bytomiu Oddzial Noworodkow Blok Va, Bytom, Poland
🇵🇱Ginekologiczno-Polozniczy Szpital Kliniczny Uniwewersytetu Medycznego im. Karola Marcinkowskiego, Poznan, Poland
🇵🇱Samodzielny Publiczny Spcjalistyczny Zaklad Opieki Zdrowotnej "Zdroje", Oddzial Noworodkow, Szczecin, Poland
Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Windtree Therapeutics
- Target Recruit Count
- 240
- Registration Number
- NCT03217825
- Locations
- 🇨🇳
Cvie Therapeutics Limited, Taipei, Taiwan
- Prev
- 1
- 2
- 3
- Next
News
Windtree Therapeutics Partners with Evofem to Manufacture FDA-Approved Contraceptive PHEXXI
Windtree Therapeutics has entered into a License and Supply Agreement with Evofem Biosciences to become the sourcing partner for PHEXXI, a hormone-free contraceptive vaginal gel that generated over $19 million in annual revenue in 2024.
Windtree's Istaroxime Shows Promise in Cardiogenic Shock Treatment and Arrhythmia Prevention
Alexandre Mebazaa presented positive Phase 2b data on istaroxime for early cardiogenic shock at the Cardiovascular Clinical Trials Conference.
Windtree Therapeutics Partners with New Growth Advisors to Explore Strategic Options for Istaroxime
Windtree Therapeutics has engaged New Growth Advisors to explore strategic options for its cardiovascular portfolio, including istaroxime, following positive Phase 2 results.
Windtree and Intensity Therapeutics Report Progress in Heart Failure and Oncology
Windtree Therapeutics reported positive Phase 2b results for istaroxime in early cardiogenic shock, showing significant improvements in cardiac function and blood pressure.
Windtree Therapeutics Initiates SEISMiC-C Trial of Istaroxime in Cardiogenic Shock
Windtree Therapeutics has begun enrolling patients in the SEISMiC-C trial to evaluate istaroxime in SCAI Stage C cardiogenic shock, a severe form of heart failure.
Windtree Therapeutics to Present Istaroxime Data at ThinkEquity Conference
Windtree Therapeutics will present a corporate update at the ThinkEquity Conference on October 30th, focusing on Istaroxime.
Istaroxime Shows Promise in Improving Cardiac Function in Early Cardiogenic Shock
Windtree Therapeutics' istaroxime significantly improved systolic blood pressure in heart failure patients with early cardiogenic shock in a Phase 2b trial.
Windtree Therapeutics Advances Istaroxime for Cardiogenic Shock
Windtree Therapeutics is nearing completion of enrollment for its Phase 2b SEISMiC Extension Study of istaroxime in early cardiogenic shock patients, with topline data expected by the end of the quarter.